OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALCOX57

Nicox SA

PharmaceuticalsVerified

Nicox SA has a total revenue of €1.8 million, with 88.13 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. Without access to profitability ratios such as net margin or ROIC, it is not possible to assess Nicox’s performance relative to industry medians. Nicox’s revenue is not segmented by geographic region or product line in the available data, so it is not possible to determine the geographic or segment concentration of its revenue. The company’s growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of €1.50, with a median and high target also at €1.50, and a mean recommendation of 2.00 (indicating a "Hold"). The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Additionally, the absence of detailed risk disclosures in source documents limits the ability to evaluate other potential risks. No recent events, such as filings or transcripts, are available in the current dataset to provide insight into the company’s recent developments.

30-day price · ALCOX-0.03 (-6.8%)
Low$0.37High$0.43Close$0.38As of16 May, 00:00 UTC
Profile
CompanyNicox SA
TickerALCOX.PA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Nicox SA is a biotechnology company focused on the development and commercialization of pharmaceutical products, primarily in the ophthalmology and urology therapeutic areas.

Classification. Nicox is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Nicox SA has a total revenue of €1.8 million, with 88.13 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. Without access to profitability ratios such as net margin or ROIC, it is not possible to assess Nicox’s performance relative to industry medians. Nicox’s revenue is not segmented by geographic region or product line in the available data, so it is not possible to determine the geographic or segment concentration of its revenue. The company’s growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of €1.50, with a median and high target also at €1.50, and a mean recommendation of 2.00 (indicating a "Hold"). The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Additionally, the absence of detailed risk disclosures in source documents limits the ability to evaluate other potential risks. No recent events, such as filings or transcripts, are available in the current dataset to provide insight into the company’s recent developments.
Key takeaways
  • Nicox SA has a total revenue of €1.8 million and 88.13 million shares outstanding, with no immediate dilution pressure.
  • Analysts have assigned a mean price target of €1.50 and a "Hold" recommendation.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • No profitability metrics or industry comparisons are available in the current dataset.
  • No recent events or filings are available to inform the company’s near-term outlook.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$1.8M
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$7.2M-$46.0M-$43.8M-$42.3M
FY-3$5.5M-$29.2M-$31.3M-$19.2M
FY-2$6.9M-$17.7M-$20.9M
FY-1$7.9M-$23.5M-$22.4M
FY0$16.8M-$15.5M-$2.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$114.6M$75.6M$42.0M
FY-3$93.2M$52.4M$16.6M
FY-2$53.0M$21.4M$11.3M
FY-1$24.4M$3.4M$10.5M
FY0$10.4M$6.0M$4.1M
PeriodOCFCapExFCFSBC
FY-4-$18.5M-$175.0k-$42.3M
FY-3-$23.1M-$42.0k-$19.2M
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.8M
FQ-6
FQ-5$4.4M
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricALCOXActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Observations
IR observations
Mean price target1.50 EUR
Median price target1.50 EUR
High price target1.50 EUR
Low price target1.50 EUR
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.13 EUR
Last actual EPS-0.03 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 00:41 UTC#fce4380c
Market quoteclose EUR 0.37 · shares 0.09B diluted
no public URL
2026-05-12 00:41 UTC#501f8c7a
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:41 UTCJob: 6f50ae17